• 1
    Lee KH, Veness MJ, Pearl-Larson T, Morgans GJ. Role of combined modality treatment of buccal mucosa squamous cell carcinoma. Aust Dent J 2005;50:108113.
  • 2
    Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309316.
  • 3
    Registry SAC. Cancer in South Australia 2006 – with projections to 2009. 2008 edn. Adelaide: South Australian Department of Health, 2008:97.
  • 4
    Australian Institute of Health and Welfare. Lip, oral cavity and pharynx for Australia (ICD10 C00-C14). Canberra: AIHW, 2010.
  • 5
    Huang SF, Kang CJ, Lin CY, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer 2008;112:10661075.
  • 6
    Daly ME, Le QT, Kozak MM, et al. Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Int J Radiat Oncol Biol Phys 2010. Jul 31 [Epub ahead of print].
  • 7
    Studer G, Furrer K, Davis BJ, et al. Postoperative IMRT in head and neck cancer. Radiat Oncol 2006;1:40.
  • 8
    Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85:156170.
  • 9
    Studer G, Zwahlen RA, Graetz KW, Davis BJ, Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol 2007;2:16.
  • 10
    Dirix P, Nuyts S. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010;78:13731380.
  • 11
    Gunn GB, Endres EJ, Parker B, Sormani MP, Sanguineti G. A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. Strahlenther Onkol 2010;186:489495.
  • 12
    Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys 2010. Oct 29 [Epub ahead of print].
  • 13
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:20912098.
  • 14
    Pignon JP, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69:S112114.
  • 15
    Shah JP, Gil Z. Current concepts in management of oral cancer–surgery. Oral Oncol 2009;45:394401.
  • 16
    O’Brien CJ, Nettle WJ, Lee KK. Changing trends in the management of carcinoma of the oral cavity and oropharynx. Aust N Z J Surg 1993;63:270274.
  • 17
    Fries R, Platz H, Wagner RR, et al. Carcinoma of the oral cavity: on the prognostic significance of the primary tumour site (by organs) in the oral cavity. J Maxillofac Surg 1980;8:2537.
  • 18
    Crile G. Landmark article Dec 1, 1906: Excision of cancer of the head and neck. With special reference to the plan of dissection based on one hundred and thirty-two operations. JAMA 1987;258:32863293.
  • 19
    Martin H, Del Valle B, Ehrlich H, Cahan WG. Neck dissection. Cancer 1951;4:441499.
  • 20
    Givi B, Andersen PE. Rationale for modifying neck dissection. J Surg Oncol 2008;97:674682.
  • 21
    Bucur A, Stefanescu L. Management of patients with squamous cell carcinoma of the lower lip and N0-neck. J Craniomaxillofac Surg 2004;32:1618.
  • 22
    P Oc, Pillai G, Patel S, et al. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol 2003;39:386390.
  • 23
    Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck 1999;21:517525.
  • 24
    Kokemueller H, Brachvogel P, Eckardt A, Hausamen JE. Neck dissection in oral cancer–clinical review and analysis of prognostic factors. Int J Oral Maxillofac Surg 2002;31:608614.
  • 25
    Patel RS, Clark JR, Gao K, O’Brien CJ. Effectiveness of selective neck dissection in the treatment of the clinically positive neck. Head Neck 2008;30:12311236.
  • 26
    Lim YC, Koo BS, Lee JS, Choi EC. Level V lymph node dissection in oral and oropharyngeal carcinoma patients with clinically node-positive neck: is it absolutely necessary? Laryngoscope 2006;116:12321235.
  • 27
    Mishra P, Sharma AK. A 3-year study of supraomohyoid neck dissection and modified radical neck dissection type I in oral cancer: with special reference to involvement of level IV node metastasis. Eur Arch Otorhinolaryngol 2010;267:933938.
  • 28
    Dixit S, Vyas RK, Toparani RB, Baboo HA, Patel DD. Surgery versus surgery and postoperative radiotherapy in squamous cell carcinoma of the buccal mucosa: a comparative study. Ann Surg Oncol 1998;5:502510.
  • 29
    Gourin CG, Johnson JT. Surgical treatment of squamous cell carcinoma of the base of tongue. Head Neck 2001;23:653660.
  • 30
    Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol 1999;35:257265.
  • 31
    Spencer KR, Ferguson JW, Wiesenfeld D. Current concepts in the management of oral squamous cell carcinoma. Aust Dent J 2002;47:284289; quiz 351.
  • 32
    Goffinet DR, Fee WE Jr, Goode RL. Combined surgery and postoperative irradiation in the treatment of cervical lymph nodes. Arch Otolaryngol 1984;110:736738.
  • 33
    Liao CT, Lee LY, Huang SF, et al. Outcome analysis of patients with oral cavity cancer and extracapsular spread in neck lymph nodes. Int J Radiat Oncol Biol Phys 2010. Oct 7 [Epub ahead of print].
  • 34
    Vikram B, Strong EW, Shah JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg 1984;6:720723.
  • 35
    Fang FM, Leung SW, Huang CC, et al. Combined-modality therapy for squamous carcinoma of the buccal mucosa: treatment results and prognostic factors. Head Neck 1997;19:506512.
  • 36
    O’Brien CJ, Smith JW, Soong SJ, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg 1986;152:456463.
  • 37
    Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998;40:529534.
  • 38
    Chandu A, Adams G, Smith AC. Factors affecting survival in patients with oral cancer: an Australian perspective. Int J Oral Maxillofac Surg 2005;34:514520.
  • 39
    Huang CJ, Chao KS, Tsai J, et al. Cancer of retromolar trigone: long-term radiation therapy outcome. Head Neck 2001;23:758763.
  • 40
    Khurana VG, Mentis DH, O’Brien CJ, Hurst TL, Stevens GN, Packham NA. Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Am J Surg 1995;170:446450.
  • 41
    Machtay M, Perch S, Markiewicz D, et al. Combined surgery and postoperative radiotherapy for carcinoma of the base of radiotherapy for carcinoma of the base of tongue: analysis of treatment outcome and prognostic value of margin status. Head Neck 1997;19:494499.
  • 42
    Shingaki S, Ohtake K, Nomura T, Nakajima T. The role of radiotherapy in the management of salivary gland carcinomas. J Craniomaxillofac Surg 1992;20:220224.
  • 43
    Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006;24:28732878.
  • 44
    Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933940.
  • 45
    Huang TL, Tsai WL, Chien CY, Lee TF, Fang FM. Quality of life for head and neck cancer patients treated by combined modality therapy: the therapeutic benefit of technological advances in radiotherapy. Qual Life Res 2010;19:12431254.
  • 46
    Mazeron R, Tao Y, Lusinchi A, Bourhis J. Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncol 2009;45:402408.
  • 47
    Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Moore-Higgs GJ, Cassisi NJ. Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue? J Clin Oncol 2000;18:3542.
  • 48
    Wang CC, Montgomery W, Efird J. Local control of oropharyngeal carcinoma by irradiation alone. Laryngoscope 1995;105:529533.
  • 49
    Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ. T4 laryngeal carcinoma: radiotherapy alone with surgery reserved for salvage. Int J Radiat Oncol Biol Phys 1998;40:549552.
  • 50
    Day TA, Davis BK, Gillespie MB, et al. Oral cancer treatment. Curr Treat Options Oncol 2003;4:2741.
  • 51
    Schwartz GJ, Mehta RH, Wenig BL, Shaligram C, Portugal LG. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck 2000;22:3441.
  • 52
    Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002;94:29672980.
  • 53
    Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 2009;45:409415.
  • 54
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949955.
  • 55
    Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003;39:560571.
  • 56
    Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006;24:593598.
  • 57
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:19451952.
  • 58
    Mohr C, Bohndorf W, Carstens J, et al. Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up). Int J Oral Maxillofac Surg 1994;23:140148.
  • 59
    Zheng JW, Qiu WL, Zhang ZY. Combined and sequential treatment of oral and maxillofacial malignancies: an evolving concept and clinical protocol. Chin Med J (Engl) 2008;121:19451952.
  • 60
    Rades D, Kronemann S, Meyners T, et al. Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2011;80:10371044.
  • 61
    Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:73507356.
  • 62
    Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994;29:243247.
  • 63
    Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561566.
  • 64
    Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885892.
  • 65
    Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246254.
  • 66
    Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:32343243.
  • 67
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567578.
  • 68
    Ayllon Barbellido S, Campo Trapero J, Cano Sanchez J, Perea Garcia MA, Escudero Castano N, Bascones Martinez A. Gene therapy in the management of oral cancer: review of the literature. Med Oral Patol Oral Cir Bucal 2008;13:E1521.
  • 69
    Ogawa F, Takaoka H, Iwai S, Aota K, Yura Y. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008;28:36373645.
  • 70
    Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K, Tanzawa H. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncol 2009;45:10211027.
  • 71
    Miyazaki A, Kobayashi J, Torigoe T, et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 2011;102:324329.
  • 72
    Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579589.
  • 73
    Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446451.
  • 74
    Porter SR, Fedele S, Habbab KM. Xerostomia in head and neck malignancy. Oral Oncol 2010;46:460463.
  • 75
    Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4:156171.
  • 76
    Logan RM. Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol 2009;45:844848.
  • 77
    Mescher A. Junqueira’s Basic Histology. 12th edn. Indiana: McGraw Hill, 2009.
  • 78
    Ong ZY, Gibson RJ, Bowen JM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010;5:22.
  • 79
    Schwenkglenks M, Pettengell R, Jackisch C, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 2011;19:483490.
  • 80
    Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007;110:16111620.
  • 81
    Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1:1824.
  • 82
    Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010;18:10611079.
  • 83
    Capote A, Escorial V, Munoz-Guerra MF, Rodriguez-Campo FJ, Gamallo C, Naval L. Elective neck dissection in early-stage oral squamous cell carcinoma–does it influence recurrence and survival? Head Neck 2007;29:311.
  • 84
    Kowalski LP, Sanabria A. Elective neck dissection in oral carcinoma: a critical review of the evidence. Acta Otorhinolaryngol Ital 2007;27:113117.
  • 85
    Ferlito A, Silver CE, Rinaldo A. Elective management of the neck in oral cavity squamous carcinoma: current concepts supported by prospective studies. Br J Oral Maxillofac Surg 2009;47:59.
  • 86
    Lung T, Tascau OC, Almasan HA, Muresan O. Head and neck cancer, treatment, evolution and post therapeutic survival. Part 2: a decade’s results 1993–2002. J Craniomaxillofac Surg 2007;35:126131.
  • 87
    Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006;66:637646.
  • 88
    Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Aust Dent J 2010;55:238244; quiz 353.